EU revises GMP guide on products derived from human blood, plasma
This article was originally published in RAJ Devices
The European Commission has substantially revised its guidance on good manufacturing practice requirements for drugs derived from human blood or plasma that is fractionated in, or imported into, the EU/European Economic Area1,2. The updated guidance also applies to stable derivatives of human blood or human plasma (eg albumin) incorporated into medical devices.
You may also be interested in...
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
The Canadian medtech regulator has recommended updating its list of recognized medical device standards that manufacturers can rely on to demonstrate compliance with local safety, effectiveness and labeling requirements.